Literature DB >> 21521776

Genomic profiles specific to patient ethnicity in lung adenocarcinoma.

Philippe Broët1, Cyril Dalmasso, Eng Huat Tan, Marco Alifano, Shenli Zhang, Jeanie Wu, Ming Hui Lee, Jean-François Régnard, Darren Lim, Heng Nung Koong, Thirugnanam Agasthian, Lance D Miller, Elaine Lim, Sophie Camilleri-Broët, Patrick Tan.   

Abstract

PURPOSE: East-Asian (EA) patients with non-small-cell lung cancer (NSCLC) are associated with a high proportion of nonsmoking women, epidermal growth factor receptor (EGFR)-activating somatic mutations, and clinical responses to tyrosine kinase inhibitors. We sought to identify novel molecular differences between NSCLCs from EA and Western European (WE) patients. EXPERIMENTAL
DESIGN: A total of 226 lung adenocarcinoma samples from EA (n = 90) and WE (n = 136) patients were analyzed for copy number aberrations (CNA) by using a common high-resolution SNP (single nucleotide polymorphism) microarray platform. Univariate and multivariate analyses were carried out to identify CNAs specifically related to smoking history, EGFR mutation status, and ethnicity.
RESULTS: The overall genomic profiles of adenocarcinomas from EA and WE patients were highly similar. Univariate analyses revealed several CNAs significantly associated with ethnicity, EGFR mutation, and smoking, but not to gender, and KRAS or p53 mutations. A multivariate model identified four ethnic-specific recurrent CNAs-significantly higher rates of copy number gain were observed on 16p13.13 and 16p13.11 in EA tumors, whereas higher rates of genomic loss on 19p13.3 and 19p13.11 were observed in tumors from WE patients. We identified several potential driver genes in these regions, showing a positive correlation between cis-localized copy number changes and transcriptomic changes.
CONCLUSION: 16p copy number gains (EA) and 19p losses (WE) are ethnic-specific chromosomal aberrations in lung adenocarcinoma. Patient ethnicity should be considered when evaluating future NSCLC therapies targeting genes located on these areas. ©2011 AACR.

Entities:  

Mesh:

Year:  2011        PMID: 21521776     DOI: 10.1158/1078-0432.CCR-10-2185

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  37 in total

1.  CCND1 G870A polymorphism interaction with cigarette smoking increases lung cancer risk: meta-analyses based on 5008 cases and 5214 controls.

Authors:  Yu-Zhong Duan; Liang Zhang; Chang-Chih Liu; Bo Zhu; Wen-Lei Zhuo; Zheng-Tang Chen
Journal:  Mol Biol Rep       Date:  2013-05-08       Impact factor: 2.316

2.  Cancer genes in lung cancer: racial disparities: are there any?

Authors:  Ahmed El-Telbany; Patrick C Ma
Journal:  Genes Cancer       Date:  2012-07

3.  Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma.

Authors:  Junichi Soh; Shinichi Toyooka; Keitaro Matsuo; Hiromasa Yamamoto; Ignacio I Wistuba; Stephen Lam; Kwun M Fong; Adi F Gazdar; Shinichiro Miyoshi
Journal:  Oncol Lett       Date:  2015-06-23       Impact factor: 2.967

4.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

5.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

Review 6.  Aryl hydrocarbon receptor and lung cancer.

Authors:  Junchieh J Tsay; Kam-Meng Tchou-Wong; Alissa K Greenberg; Harvey Pass; William N Rom
Journal:  Anticancer Res       Date:  2013-04       Impact factor: 2.480

7.  Detection of c-kit mutational status in small-cell lung cancer in a Chinese cohort.

Authors:  Ying Cheng; Hui Li; Lixia Ma; Shuang Zhang; Shi Yan; Jing Zhu; Sheng Wang; Rui Zhang; Kai Niu; Yawen Liu
Journal:  Thorac Cancer       Date:  2014-04-22       Impact factor: 3.500

Review 8.  Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Anthony J Alberg; Malcolm V Brock; Jean G Ford; Jonathan M Samet; Simon D Spivack
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  Genomic characteristics in neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma.

Authors:  Wenwu He; Xuefeng Leng; Kangning Wang; Tiaoqin Mao; Lin Peng; Qiang Fang; Wenguang Xiao; Yongtao Han
Journal:  J Gastrointest Oncol       Date:  2020-12

10.  Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.

Authors:  Wenlei Zhuo; Liang Zhang; Bo Zhu; Junjun Ling; Zhengtang Chen
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.